SIT Pharma is pleased to announce the acquisition of DERINOX® from Therabel Lucien Pharma Sas.
DERINOX® is a decongestant for topical use for short-term local symptomatic treatment of congestive and inflammatory conditions during acute rhinitis, in adults and adolescents over 15 years of age.
Silvia Lunati, SIT Pharma’s General Manager, comments “This acquisition confirms and further strengthens our long term grown trajectory consolidating our positioning for the French branch of SIT in France Market (DESMA Pharma)”.
This new achievement confirms SIT Pharma as a reliable partner for international acquisitions of mature branded medicines. SIT Pharma, moreover, confirms the objective to maintain the actual distribution network and so ensure DERINOX® business continuity.
About SIT Pharma
SIT Pharma is a family-owned pharmaceutical company, based in Italy since 1927. Today is an international pharmaceutical group with almost 100 years of experience and a history of prestigious acquisitions and global expansion. SIT Pharma is a reliable preferred acquirer for pharma businesses choosing to divest their “mature”, “established” or “tail” off-patent branded medicines.
In our manufacturing plants we assure to continue the high-quality manufacturing and the management of the medicines, aspiring to breathe new life into the medicines, investing great resources to renew the life cycle and give new stability and sustainability over the long-term.
SIT Pharma is present in five continents and in over seventy countries worldwide.
